VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

In this study, Black patients had higher rates of diabetes (10% vs 7.1%, P<0.001) and average BMI (39.4 vs 39.1 ... the researchers explained. One silver lining was that these discussions became ...

Kitchen appliances don't have to be bland or eyesores — these brands are the ones to know for fitting out your kitchen or ...

Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck's (MRK) diabetes drug Janumet. "The Biden-Harris ...

"Released in 1989, the Air Jordan 4 was the first global release of the franchise, and the first shoe in the line to feature its signature “over-molded” mesh. Another notable feature on the Air Jordan ...

That is when a new study of the drug is also planned — details were shared in Novo's earnings presentation, released today, and Redefine 4 study results have been promised for H225. Novo stock ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

Novo Nordisk closed up 4.5% Wednesday. Shares of obesity drug rival Eli Lilly, meanwhile, rose 1.4%. Speaking to CNBC Wednesday, CEO and President Lars Fruergaard Jørgensen said that the company ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. Get access to your new suite of ...